EXACT Sciences (NASDAQ:EXAS) Rating Reiterated by Stifel Nicolaus

Share on StockTwits

EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating reissued by equities research analysts at Stifel Nicolaus in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $110.00 price objective on the medical research company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 12.04% from the company’s previous close.

Several other research analysts have also weighed in on the company. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Jefferies Financial Group decreased their target price on EXACT Sciences from $138.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Leerink Swann decreased their target price on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Citigroup started coverage on EXACT Sciences in a report on Monday, January 6th. They set a “buy” rating and a $120.00 target price on the stock. Finally, ValuEngine raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. EXACT Sciences currently has a consensus rating of “Buy” and an average price target of $121.00.

NASDAQ:EXAS opened at $98.18 on Friday. The firm has a market capitalization of $12.58 billion, a price-to-earnings ratio of -57.41 and a beta of 1.36. EXACT Sciences has a twelve month low of $75.35 and a twelve month high of $123.99. The stock’s 50 day moving average price is $94.13 and its two-hundred day moving average price is $97.43. The company has a quick ratio of 2.63, a current ratio of 2.75 and a debt-to-equity ratio of 0.67.

EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.91. The firm had revenue of $295.58 million for the quarter, compared to analyst estimates of $294.39 million. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. As a group, analysts anticipate that EXACT Sciences will post -1.64 earnings per share for the current year.

In related news, insider G Bradley Cole sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $90.30, for a total transaction of $903,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.20% of the stock is currently owned by insiders.

Hedge funds have recently bought and sold shares of the stock. Valeo Financial Advisors LLC boosted its stake in EXACT Sciences by 154.6% in the 4th quarter. Valeo Financial Advisors LLC now owns 443 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 269 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in EXACT Sciences by 129.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 497 shares of the medical research company’s stock worth $45,000 after purchasing an additional 280 shares in the last quarter. Shine Investment Advisory Services Inc. increased its holdings in EXACT Sciences by 31.8% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock worth $47,000 after purchasing an additional 125 shares in the last quarter. Coastal Investment Advisors Inc. increased its holdings in EXACT Sciences by 65.7% in the 3rd quarter. Coastal Investment Advisors Inc. now owns 648 shares of the medical research company’s stock worth $59,000 after purchasing an additional 257 shares in the last quarter. Finally, Bridger Capital Management LLC acquired a new position in EXACT Sciences in the 3rd quarter worth about $68,000. 87.01% of the stock is currently owned by institutional investors and hedge funds.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: How is a buy-side analyst different from a sell-side analyst?

Analyst Recommendations for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Weekly Investment Analysts’ Ratings Updates for Killam Apartment REIT
Weekly Investment Analysts’ Ratings Updates for Killam Apartment REIT
Somewhat Positive Press Coverage Extremely Likely to Affect Metro Bank  Share Price
Somewhat Positive Press Coverage Extremely Likely to Affect Metro Bank Share Price
Kinder Morgan  Sets New 12-Month High at $22.13
Kinder Morgan Sets New 12-Month High at $22.13
New York Times  Hits New 1-Year High at $39.80
New York Times Hits New 1-Year High at $39.80
Plantronics  Hits New 1-Year Low at $13.83
Plantronics Hits New 1-Year Low at $13.83
iShares S&P 500 Growth ETF  Sets New 52-Week High at $210.33
iShares S&P 500 Growth ETF Sets New 52-Week High at $210.33


 
© 2006-2020 Zolmax.